

**5<sup>th</sup>**

*International  
Conference on*

# **Thrombosis and Hemostasis Issues in Cancer**

*Stresa, Italy - April 23-25, 2010*



**Program**



**ICTHIC**

**[www.icthic.com](http://www.icthic.com)**

# SPONSORS

## Platinum



## Gold



## Silver



## Bronze



**5<sup>th</sup>**

*International  
Conference on*

# **Thrombosis and Hemostasis Issues in Cancer**

*Stresa, Italy - April 23-25, 2010*

**Program**





## CONFERENCE CHAIRMEN

### **Anna Falanga**

Division of Immunohematology and Transfusion Medicine  
& Hemostasis and Thrombosis Center  
A.O. Ospedali Riuniti di Bergamo  
Largo Barozzi, 1 - 24128 Bergamo, Italy  
e-mail: annafalanga@yahoo.com

### **Benjamin Brenner**

Rambam Medical Center & Bruce  
Rappaport Faculty of Medicine  
Institute of Hematology  
P.O. Box 9602  
Haifa 31096, Israel  
e-mail: b\_brenner@rambam.health.gov.il

### **Frederick R. Rickles**

The George Washington University  
2300 Eye St NW  
Washington, DC 20037, USA  
e-mail: frederick.rickles@gmail.com

## ORGANIZING COMMITTEE

Anna FALANGA   Benjamin BRENNER   Frederick R. RICKLES  
Tiziano BARBUI   Roberto LABIANCA   Marina MARCHETTI  
Galit SARIG   Alfonso VIGNOLI   Elena GATTI   Laura RUSSO

## SCIENTIFIC SECRETARIAT

### **Anna Falanga Marina Marchetti Alfonso Vignoli**

Division of Immunohematology and Transfusion Medicine  
& Hemostasis and Thrombosis Center  
A.O. Ospedali Riuniti di Bergamo  
Largo Barozzi, 1 - 24128 Bergamo, Italy  
e-mail: icthic2010@yahoo.com

## ORGANIZING SECRETARIAT



**C.E.C. Srl**

**Servizi Congressuali ed Eventi Culturali**

Via G. Verdi 18 - 24121 Bergamo - Italy  
Phone +39.035.249899 - Fax +39.035.237852  
E-mail: info@icthic.com





AUSPICES

## The meeting will be held under the auspices of:



Città di Stresa



Ospedali Riuniti di Bergamo



Associazione Italiana  
di Oncologia Medica



EUROPEAN  
HEMATOLOGY  
ASSOCIATION



European Society  
for Medical Oncology



Federazione Centri  
Sorveglianza Anticoagulati



Società Italiana di Ematologia



Società Italiana per lo Studio  
dell'Emostasi e della Trombosi



# Program Overview

	Friday April 23 <sup>rd</sup> , 2010	Saturday April 24 <sup>th</sup> , 2010	Sunday April 25 <sup>th</sup> , 2010	
8.00→	Registration	Registration	Registration	←8.00
8.30→				←8.30
8.45→				←8.45
9.00→		Plenary Session 2 Thromboprophylaxis in Cancer Patients <i>Auditorium</i>	Plenary Session 4 Updated Guidelines for Prevention and Treatment of VTE in Cancer <i>Auditorium</i>	←9.00
9.15→				←9.15
9.30→				←9.30
9.45→				←9.45
10.00→				←10.00
10.15→				←10.15
10.30→				←10.30
10.45→		Coffee Break	Coffee Break	←10.45
11.00→	Satellite Symposium LEO Pharma <i>Auditorium</i>	Simultaneous Session 1 Biology of Blood Coagulation <i>Room C</i>	Simultaneous Session 5 Targeting Hemostatic System as Therapy for Cancer <i>Room C</i>	←11.00
11.15→		Simultaneous Session 2 Bleeding Issues <i>Auditorium</i>	Simultaneous Session 6 Gender- and Age-Related Issues <i>Auditorium</i>	←11.15
11.30→				←11.30
11.45→				←11.45
12.00→				←12.00
12.15→				←12.15
12.30→				←12.30
12.45→				←12.45
13.00→				←13.00
13.15→				←13.15
13.30→		Lunch Session Sanofi Aventis <i>Room C</i>	Lunch	←13.30
13.45→				←13.45
14.00→				←14.00
14.15→			Poster Discussion Sessions Session 1: Room C Session 2: Room D Session 3: Room E	←14.15
14.30→		Plenary Session 3 Antitumor Properties of Anticoagulants <i>Auditorium</i>		←14.30
14.45→				←14.45
15.00→	Congress Opening: Opening Remarks  Simon Karparkin Memorial Lecture			←15.00
15.15→				←15.15
15.30→				←15.30
15.45→				←15.45
16.00→	Plenary Session 1 Risk Factors for Thrombosis in Cancer <i>Auditorium</i>	Coffee Break	Poster Discussion Sessions Session 4: Room D Session 5: Room C Session 6: Room E	←16.00
16.15→				←16.15
16.30→				←16.30
16.45→	Coffee Break			←16.45
17.00→	Plenary Session 1 (cont'd) Risk Factors for Thrombosis in Cancer <i>Auditorium</i>	Simultaneous Session 3 Micro-particles in Tumor Growth <i>Room C</i>	Meeting Closed	←17.00
17.15→		Simultaneous Session 4 Biology of Blood Coagulation <i>Auditorium</i>		←17.15
17.30→				←17.30
17.45→				←17.45
18.00→	Debate Thromboprophylaxis during Chemotherapy <i>Auditorium</i>			←18.00
18.15→				←18.15
18.30→				←18.30
18.45→				←18.45
19.00→				←19.00
19.15→				←19.15
19.30→				←19.30
19.45→				←19.45
20.00→	Welcome Cocktail	Gala Dinner	Farewell Party	←20.00
20.15→				←20.15
20.30→				←20.30



## SATELLITE SYMPOSIA & LUNCH SESSION

**Friday - April 23<sup>rd</sup>, 2010**



**9.30 - 12.45**  
not CME accredited

### **LEO Symposium** (Auditorium)

#### **BEATING BLOOD CLOTS CHALLENGES IN THE TREATMENT AND PREVENTION OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: AN INTERACTIVE SYMPOSIUM**

Chairs: A.Y.Y. Lee (Canada), R. Bauersachs (Germany)

**Welcome and introduction** A.Y.Y. Lee, R. Bauersachs

**Diagnosis and treatment of VTE in cancer - difficult clinical decisions**  
P. Kamphuisen (The Netherlands)

**Management of cancer patients with VTE: what to do when evidence is lacking?** S. Noble (UK)

#### **Coffee break**

**VTE Guidelines: the oncologist's view.** A.A. Khorana (USA)

**Introduction to interactive session.** A.Y.Y. Lee, R. Bauersachs

**Case 1.** R. Bauersachs

**Case 2.** G. Meyer (France)

**Summary.** A.Y.Y. Lee, R. Bauersachs

**Friday - April 23<sup>rd</sup>, 2010**



**9.00 - 10.45**  
not CME accredited

### **PFIZER Symposium** (Room C)

#### **CANCER-ASSOCIATED THROMBOSIS: CAN WE MEET THE CHALLENGE?**

Chair: A.K. Kakkar (UK)

**Opening.** A.K. Kakkar

**Cancer-associated thrombosis - is it always irrelevant?** H.A. Liebman (USA)

**Can we reliably predict who is at risk?** C. Francis (USA)

**Treating VTE in Cancer.** A.K. Kakkar

**Case study 1: Central venous catheters.** B. Brenner (Israel)

**Case study 2: Prophylaxis of a cancer patient undergoing surgery.**  
C. Francis

**Case study 3: Asymptomatic VTE found during staging.** H.A. Liebman

**Case study 4: Treatment of cancer associated thrombosis.** A.K. Kakkar

**Case study 5: Haematological cancer patient.** B. Brenner

**Questions and answers**

**Closing remarks.** A.K. Kakkar



## SATELLITE SYMPOSIA & LUNCH SESSION

### Friday - April 23<sup>rd</sup>, 2010



GlaxoSmithKline

#### **GSK Symposium (Room C)**

**11.30 - 12.45**  
not CME accredited

#### **NEW DEVELOPMENTS IN LMWH BENEFITS FOR CANCER PATIENTS**

Chairs: H.R. Büller (The Netherlands), A. Falanga (Italy)

**Introduction.** H.R. Büller

**VTE prevention following cancer surgery.** W. Ageno (Italy)

**VTE prevention during chemotherapy.** G. Agnelli (Italy)

**VTE treatment in cancer patients.** A.T. Cohen (UK)

**ESMO guidelines: VTE management with LMWH in cancer patients.**

A. Falanga

**Q&A session**

### Saturday - April 24<sup>th</sup>, 2010



#### **SANOFI-AVENTIS Lunch Session (Room C)**

**13.00 - 14.00**  
not CME accredited

#### **VTE IN ONCOLOGY - FROM GUIDELINES TO CLINICAL PRACTICE**

Chairs: B. Brenner (Israel), W. Ageno (Italy)

**Introduction.** B. Brenner

**VTE risk in oncology: suggestions and open issues in guidelines.**

G. Palareti (Italy)

**VTE treatment in cancer.** D. Imberti (Italy)

**Discussion**





**Friday - April 23<sup>rd</sup>, 2010**

## **SATELLITE SYMPOSIA**

(see pages 7 and 8)

## **CONGRESS OPENING (Auditorium)**

- 14.30 - 15.00**     **Opening Remarks:**  
Conference Chairmen: A. Falanga, B. Brenner, F.R. Rickles
- 15.00 - 15.45**     **Simon Karpatkin Memorial Lecture**  
**Platelets: guardians of tumor vasculature**  
D. Wagner (USA),  
Introduced by F.R. Rickles

## **SCIENTIFIC SESSIONS (Auditorium)**

- 15.45 - 17.40**     **Plenary Session 1**  
**RISK FACTORS FOR THROMBOSIS IN CANCER**  
Chairs: M.H. Prins (The Netherlands), P.M. Mannucci (Italy)
- 15.45 - 16.10**     **Risk stratification and models** **PL-01**  
A.A. Khorana (USA)
- 16.10 - 16.35**     **The roles of anticoagulants in patients with cancer** **PL-02**  
A.Y.Y. Lee (Canada)
- 16.35 - 17.00**     **Coffee break**
- 17.00 - 17.25**     **Tests predictive of thrombosis in cancer** **PL-03**  
I. Pabinger (Austria)  
[Selected Abstract](#)
- 17.25 - 17.40**     **Prognostic relevance of asymptomatic venous thromboembolism in patients with cancer** **OC-01**  
[F. Dentali](#), W. Ageno, M. Giorgi Pierfranceschi, D. Imberti, A. Malato, C. Nitti, A. Salvi, S. Siragusa, A. Squizzato, A. Venco, J. Vitale, G. Agnelli. (Italy)
- 17.45 - 18.45**     **Debate**  
**THROMBOPROPHYLAXIS DURING CHEMOTHERAPY**  
Chair: C. Francis (USA)  
**Introduction:** C. Francis  
**NO:** M.N. Levine (Canada)  
**YES:** G. Agnelli (Italy)

**19.00**     **Welcome Cocktail Room Panoramica, Palazzo dei Congressi**



## Saturday - April 24<sup>th</sup>, 2010

- 8.30 - 10.30**      **Plenary Session 2 (Auditorium)**  
with the contribution of Bayer Schering Pharma  
**THROMBOPROPHYLAXIS IN CANCER PATIENTS**  
Chairs: H.A. Liebman (USA), P. Prandoni (Italy)
- 8.30 - 8.55**      **Thromboprophylaxis for medical patients** **PL-04**  
A.T. Cohen (UK)
- 8.55 - 9.20**      **Thromboprophylaxis for cancer surgery** **PL-05**  
A.K. Kakkar (UK)
- 9.20 - 9.45**      **New anticoagulants for patients with cancer** **PL-06**  
J.I. Weitz (Canada)
- Selected Abstracts
- 9.45 - 10.00**      **Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)** **OC-02**  
A. Maraveyas, J. Waters, R. Roy, D. Propper, D. Fyfe, F. Lofts, G. Bozas, E. Gardiner, J. Sgouros, K.R. Wedgewood. (UK)
- 10.00 - 10.15**      **Randomized phase II trial of an oral factor Xa inhibitor in patients with metastatic cancer on chemotherapy** **OC-03**  
M.N. Levine, H.A. Liebman, C.P. Esclanate, J.A. Julian, D. Deitchman, M.C. O'Brien, L.M. Ramirez. (Canada)
- 10.15 - 10.30**      **Discussion**
- 10.30 - 11.00**      **Coffee Break**

## SIMULTANEOUS SESSIONS

- 11.00 - 13.00**      **Simultaneous Session 1 (Room C)**  
**BIOLOGY OF BLOOD COAGULATION**  
Chairs: J. Degen (USA), R. Giavazzi (Italy)
- 11.00 - 11.25**      **Signaling and procoagulant contributions of tissue factor to cancer progression** **SS-01**  
W. Ruf (USA)
- 11.25 - 11.50**      **Mechanisms coupling thrombin generation to colitis-associated cancer** **SS-02**  
J. Palumbo (USA)
- 11.50 - 12.15**      **Activation of clotting proteins by tumor genetic programs** **SS-03**  
J.W. Rak (Canada)



## Selected Abstracts

- 12.15 - 12.30**     **Expression of protease activated receptor-1 and tissue factor in human cancers determined by gene expression profiling and laser capture microdissection** **OC-04**  
C. Haslinger, C. Rupp, H. Dolznig, N. Schweifer, J. van Ryn,  
P. Garin-Chesa. (Austria, Germany)
- 12.30 - 12.45**     **Inhibition of tissue factor by Ixolaris reduces primary tumor growth and metastasis in a murine model of melanoma** **OC-05**  
A. Da Silva de Oliveira, L.G. Lima, D.E. Machado, L.E. Nasciutti, L.C. Petersen,  
I.M.B. Francischetti, R.Q. Monteiro. (Brazil, Denmark, USA)
- 12.45 - 13.00**     **Discussion**
- 11.00 - 13.00**     **Simultaneous Session 2 (Auditorium)**  
**BLEEDING ISSUES**  
Chairs: M. Levi (The Netherlands), A. Federici (Italy)
- 11.00 - 11.25**     **Open issues in acute promyelocytic leukemia** **SS-04**  
M. Sanz (Spain)
- 11.25 - 11.50**     **Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact** **SS-05**  
F. Elice, F. Rodeghiero (Italy)
- 11.50 - 12.15**     **Bleeding complications associated with anticoagulant therapy in patients with cancer** **SS-06**  
M. Monreal (Spain)

## Selected Abstracts

- 12.15 - 12.30**     **Frequency, types and management of bleeding episodes in acquired von Willebrand syndrome: a five-year prospective study in a cohort of 18 patients with chronic lympho-myeloproliferative disorders (LPD/MPD)** **OC-06**  
A.B. Federici, F. Rezzonico, P. Bucciarelli, A. Artoni, M.T. Canciani, G. Cozzi. (Italy)
- 12.30 - 12.45**     **Heparin-antagonist PMX-60056 rapidly and completely reverses heparin anticoagulation in man** **OC-07**  
R.E. McAllister. (USA)
- 12.45 - 13.00**     **Discussion**



## Saturday - April 24<sup>th</sup>, 2010 (cont'd)

- 13.00 - 14.00 Lunch Session (Room C)** (see page 8)
- 14.00 - 16.05 Plenary Session 3 (Auditorium)**  
**ANTITUMOR PROPERTIES OF ANTICOAGULANTS**  
Chairs: F.R. Rickles (USA), G. Palareti (Italy)
- 14.00 - 14.10 Update on the predictive value of D-dimer in patients with idiopathic VTE** **PL-07**  
G. Palareti (Italy)
- 14.10 - 14.35 Experimental approaches and new drugs** **PL-08**  
L. Borsig (Switzerland)
- 14.35 - 15.00 Heparanase procoagulant effects and inhibition by heparins** **PL-09**  
Y. Nadir (Israel)
- 15.00 - 15.25 Anticoagulants in mouse models** **PL-10**  
C. J. Van Noorden (The Netherlands)
- 15.25 - 15.50 Clinical evidence for use of LMWH as adjuvant therapy in patients with cancer** **PL-11**  
H.R. Büller (The Netherlands)
- Selected Abstract
- 15.50 - 16.05 Adjuvant Bemiparin in small cell lung cancer: results from the ABEL Study** **OC-08**  
R. Lecumberri, B. Massuti, G. López Vivanco, A. Font, E. González Billalabeitia, E. Rocha, on behalf of the ABEL Investigators. (Spain)
- 16.10 - 16.30 Coffee Break**

## SIMULTANEOUS SESSIONS

- 16.30 - 18.30 Simultaneous Session 3 (Room C)**  
**MICROPARTICLES IN TUMOR GROWTH**  
Chairs: F. Dignat-George (France), F.R. Rickles (USA)
- 16.30 - 16.55 Membrane microparticles in VTE and cancer: Actors or artifacts** **SS-07**  
N. Key (USA)
- 16.55 - 17.20 Microparticles in cancer disease and progression** **SS-08**  
J.M. Freyssinet (France)
- 17.20 - 17.45 Predictive value of TF-bearing microparticles in VTE/cancer patients** **SS-09**  
J.I. Zwicker (USA)





## Selected Abstracts

- 17.45 - 18.00** **Tissue factor-bearing microparticles released from tumor cells: Relationship of particle size to procoagulant activity** **OC-09**  
J.L. Francis, M. Davila, L. Robles, A. Amirkhosravi. (USA)
- 18.00 - 18.15** **Involvement of cancer cell-derived microparticles on thrombus formation in vivo** **OC-10**  
C. Dubois, G.M. Thomas, L. Panicot-Dubois, R. Lacroix, F. Dignat-George, D. Lombardo. (France)
- 18.15 - 18.30** **Discussion**
- 16.30 - 18.25** **Simultaneous Session 4 (Auditorium)**  
with the contribution of Alexion  
**THROMBOTIC COMPLICATIONS**  
Chairs: R. White (USA), M.-M. Samama (France)
- 16.30 - 16.55** **Population based studies** **SS-10**  
M.B. Donati (Italy)
- 16.55 - 17.20** **VTE in acute leukemia, lymphoma and myeloma** **SS-11**  
T. Wun (USA)
- 17.20 - 17.45** **The risk of cancer in OAT patients** **SS-12**  
V. Pengo (Italy)
- 17.45 - 18.10** **Paroxysmal nocturnal hemoglobinuria and thrombosis** **SS-13**  
I.C. Weitz (USA)

## Selected Abstract

- 18.10 - 18.25** **Residual vein thrombosis (RVT) for assessing the optimal management of deep vein thrombosis in cancer patients: An interim analysis of the cancer DACUS study** **OC-11**  
A. Malato, W. Ageno, E. Bucherini, O. Cormaci, A. D'Alessio, P. Di Micco, P. Galluci, G. La Marca, L. LoCoco, D. Mascheroni, T. Prantera, F. Recchia, S. Rotondo, G. Saccullo, R. Santoro, P. Spadaro, O. Urbano, S. Siragusa. (Italy)

**19.30** **Gala Dinner at the Hotel Regina Palace**



## Sunday - April 25<sup>th</sup>, 2010

<b>8.30 - 10.30</b>	<b>Plenary Session 4 (Auditorium)</b> <b>UPDATED GUIDELINES FOR PREVENTION AND TREATMENT OF VTE IN CANCER</b> Chairs: F.R. Rosendaal (The Netherlands), A. Falanga (Italy)	
<b>8.30 - 8.55</b>	<b>French guidelines</b> D. Farge-Bancel (France)	<b>PL-12</b>
<b>8.55 - 9.20</b>	<b>ESMO guidelines</b> R. Labianca (Italy)	<b>PL-13</b>
<b>9.20 - 9.45</b>	<b>ASCO guidelines</b> G.H. Lyman (USA)	<b>PL-14</b>
<b>9.45 - 10.10</b>	<b>NCCN guidelines</b> M. Streiff (USA)	<b>PL-15</b>
<b>10.10 - 10.30</b>	<b>Round table on unresolved issues</b> Chair: G.H. Lyman	
<b>10.30 - 11.00</b>	<b>Coffee Break</b>	

## SIMULTANEOUS SESSIONS

<b>11.00 - 13.00</b>	<b>Simultaneous Session 5 (Room C)</b> <b>TARGETING HEMOSTATIC SYSTEM AS THERAPY FOR CANCER</b> Chairs: H. ten Cate (The Netherlands), P.M. Sandset (Norway)	
<b>11.00 - 11.25</b>	<b>Targeting tumor vessel anionic phospholipids: experimental and clinical studies</b> P.E. Thorpe (USA)	<b>SS-14</b>
<b>11.25 - 11.50</b>	<b>The role of activated protein C in tumor metastasis</b> G.L. Van Sluis (The Netherlands)	<b>SS-15</b>
<b>11.50 - 12.15</b>	<b>Vascular targeting with TF constructs</b> W.E. Berdel (Germany) <a href="#"><u>Selected Abstracts</u></a>	<b>SS-16</b>
<b>12.15 - 12.30</b>	<b>Tissue factor phosphorylation requires protease activated receptor-2 expression: Correlation with the prognosis of human breast cancer</b> <u>M. Belting</u> , L. Rydén, D. Grabau, F. Schaffner, P.-E. Jönsson, W. Ruf. (Sweden, USA)	<b>OC-12</b>
<b>12.30 - 12.45</b>	<b>Enhanced expression of MDA-9/syntenin induced through the tissue-factor pathway in melanoma promotes tumor cell migration and invasion</b> <u>H. Boukerche</u> , H. Aissaoui, C. Prévost, H.J.C. Bordet, J.L. Plantier, Y. Dargaud, P.B. Fisher, C. Négrier. (France, USA)	<b>OC-13</b>
<b>12.45 - 13.00</b>	<b>Discussion</b>	



<b>11.00 - 13.00</b>	<b>Simultaneous Session 6 (Auditorium)</b> <b>GENDER- AND AGE-RELATED ISSUES</b> Chairs: U. Nowak-Göttl (Germany), B. Brenner (Israel)	
<b>11.00 - 11.25</b>	<b>Thrombohemorrhagic complications in children with hemato-oncological diseases</b> M.C. Putti (Italy)	<b>SS-17</b>
<b>11.25 - 11.50</b>	<b>Epidemiology and risk factors for VTE in female cancer</b> N. Kuderer (USA)	<b>SS-18</b>
<b>11.50 - 12.15</b>	<b>Thrombosis in male cancer</b> J. Beyer-Westendorf (Germany)	<b>SS-19</b>
	<u>Selected Abstracts</u>	
<b>12.15 - 12.30</b>	<b>Reversible posterior leukoencephalopathy syndrome: the role of von Willebrand Factor and ADAMTS13 in children with ALL during induction therapy</b> <u>J.D.A. Carneiro</u> , E.A. D'Amico, V. Odone-Filho, D.A.F. Chamone. (Brazil)	<b>OC-14</b>
<b>12.30 - 12.45</b>	<b>Hemostatic activation, fibrinolysis and angiogenesis are increased in patients with advanced prostate cancer (PC) and decrease in response to hormonal therapy</b> <u>J.E. Arnason</u> , S. Hong, G. S. Dhillon, S. Banerjee, E. Gorynski, M. Levandovsky, K. Petrillo, J. Selzer, D. M. Nanus, S. T. Tagawa. (USA)	<b>OC-15</b>
<b>12.45 - 13.00</b>	<b>Discussion</b>	
<b>13.00 - 14.00</b>	<b>Lunch</b>	
<b>POSTER DISCUSSION SESSIONS (Rooms C, D, E, see pages 16-21)</b>		
<b>14.00 - 15.15</b>	<b>Sessions 1-2-3</b>	
<b>15.45 - 17.00</b>	<b>Sessions 4-5-6</b>	
<b>17.00</b>	<b>Meeting Closed</b>	
<b>19.30</b>	<b>Farewell Party on the island Isola Bella</b>	



## Poster Session 1: EPIDEMIOLOGY

### Room C

Chairs: M. Mandalà (Italy), M. Verso (Italy)

Sunday - April 25<sup>th</sup>, 2010  
14.00 - 15.15

- PO-01 Venous thromboembolism in patients with lung cancer**  
C. Font\*, M. Campayo, B. Farrús, D. Tàssies, J.C. Reverter, N. Reguart, N. Viñolas, P. Gascon (Spain)
- PO-02 Incidence of venous thromboembolism and prophylaxis use in ambulatory cancer patients receiving chemotherapy**  
E. Panizo, R. Lecumberri\*, S. Varea, A. García-Mouriz, J.A. Páramo (Spain)
- PO-03 Incidence and risk factors for venous thromboembolism in cancer patients qualifying for chemotherapy**  
G. van Sluis\*, L. Verberne, M. Kok, J.C. van Houwelingen, H.R. Buller, H.-M.M.B. Otten (The Netherlands)
- PO-04 Prevalence of venous thromboembolism in upper gastrointestinal cancer at time of diagnosis**  
A.C. Larsen\*, T. Dabrowski, R. Vincents Fisker, S. Risom Kristensen, B. Kuno Møller, O. Thorlacius-Ussing (Denmark)
- PO-05 Incidental pulmonary emboli in cancer patients - a single centre experience**  
O.G. Donnelly, J. Jones, B. Carey, D. Swinson, G. Radhakrishna\* (UK)
- PO-06 Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon**  
N. Ferrante\*, M. Di Nisio, M. De Tursi, S. Iacobelli, F. Cuccurullo, H. R. Buller, E. Porreca (Italy, The Netherlands)
- PO-07 Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis**  
F. Dentali\*, W. Ageno, C. Becattini, L. Galli, M. Gianni, N. Riva, D. Imberti, A. Squizzato, A. Venco, G. Agnelli (Italy)
- PO-08 Venous thromboembolism in cancer outpatients receiving chemotherapy for solid tumors.**  
C. Font\*, B. Farrús, L. Vidal, V. Ortega, M. Campayo, D. Tàssies, J.C. Reverter, P. Gascon (Spain)
- PO-09 Pulmonary embolism as an incidental finding in ambulatory cancer outpatients. Characteristics and outcome**  
G. Bozas\*, S. Ramasamy, G. Avery, A. Maraveyas (UK)
- PO-10 Cancer associated thrombosis: the Thai perspective**  
P. Angchaisuksiri\*, D. Worasayan (Thailand)
- PO-11 Venous thromboembolism in patients receiving preoperative chemotherapy for gastric cancer**  
A.C. Larsen\*, K.G. Sunesen, T. Dabrowski, R. Vincents Fisker, M.K. Yilmaz, O. Thorlacius-Ussing (Denmark)
- PO-12 Safety and feasibility of a diagnostic algorithm combining clinical probability, D-dimer test and ultrasonography in suspected upper extremity deep vein thrombosis**  
A. Kleinjan\*, M. Di Nisio, P.W. Kamphuisen, H.R. Buller on behalf of the steering committee (The Netherlands, Italy)
- PO-13 Deep vein thrombosis of the upper limbs. A retrospective study.**  
R. Tasinato\*, I. Salloum, M. Godina, P. Menegon, A. Vecchiato (Italy)
- PO-14 Unsuspected venous thromboembolic disease as a finding of staging procedures in oncology.**  
P. Cravero\*, R. Conti, R. Burgos, P. Ochoa, J.P. Sade, C. Martin, F. Petracci, M. Aguirre, G. Giornelli, J. O'Connor, M.C. Foncuberta, M. Zylberman, N. Tartas, R. Chacon, J. Sanchez Avalos (Argentina)
- PO-15 Cancer-related venous thrombosis: residual vein thrombosis improves screening for occult cancer**  
A. Malato\*, F. Fulfaro, L. Lo Coco, G. Saccullo, V. Abbadessa, N. Gebbia, S. Siragusa (Italy)
- PO-16 Upper arm deep venous thrombosis in peripheral inserted central venous catheter (PICC): data in our oncologic patients population.**  
E. Romagnoli\*, L. Simioni, P. Bullian, G. Masia, B. Fai, M. Cecconello, R. Segati (Italy)





## Poster Session 2: HEMOSTATIC ACTIVATION AND CANCER PROGRESSION

### Room D

Chairs: H.H. Versteeg (The Netherlands), R. Lorenzet (Italy)

Sunday - April 25<sup>th</sup>, 2010  
14.00 - 15.15

- PO-17 Surgical stress promotes the development of metastatic disease by a coagulation-dependent mechanism**  
R. Auer\*, R. Seth, L. MacKenzie, J. Bell, H. Atkins, R. Boushey, M. Carrier (Canada)
- PO-18 Tissue factor expression is associated with MMP and uPA/PAI secretion in adherent small cell lung cancer cells**  
N. Hahn, R. Seitz, M. Heiden, U. Salge-Bartels\* (Germany)
- PO-19 On the role of protease-activated receptors -1 and -2 (PAR-1 and PAR-2) in human glioblastoma cell lines**  
A. Dutra-Oliveira\*, T.C. Carneiro-Lobo, I. Bakker-Abreu, J. Scharfstein, R.Q. Monteiro, A. Mariano-Oliveira (Brazil)
- PO-20 Organic metallic complexes with antiplatelet and antineoplastic effects**  
S. Karkabounas, P. Veltsistas, R. Liasko, A. Metsios, M.P. Makris, A. Evangelou, P.E. Makris\* (Greece)
- PO-21 Characterization of tumor cells thrombin generation (TG) capacity by the calibrated automated assay (CAT)**  
M. Marchetti\*, E. Diani, E. Cantalino, H. ten Cate, A. Falanga (Italy, The Netherlands)
- PO-22 Sodium butyrate stimulates over-expression of TFPI in CHO-K1 cells**  
G. Skretting\*, B. Stavik, E. Solheim, N. Iversen, P. M. Sandset (Norway)
- PO-23 Chemotherapy-induced venous thromboembolism is not due to endothelial cell activation**  
C.C. Kirwan\*, G.J. Byrne, G. McDowell, N.J. Bundred, C.N. McCollum (UK)
- PO-24 Oxidative changes in blood plasma of patients with myelodysplastic syndromes**  
J. Suttner\*, P. Majek, K. Pimkova, J. Cermak, R. Kotlin, J.E. Dyr (Czech Republic)
- PO-25 Platelets as the biomarkers of cancer therapy efficiency**  
A. Matveeva\*, S. Babakova, O. Bichenkov, I. Vasilenko (Russia)
- PO-26 Coagulation activation in myeloid leukemia: the role of integrin CD11b, leukocytosis, blast cells and promyelocytes**  
L. Sukrisman\*, K.L. Tambunan, A.R. Harahap, B. Sutrisna (Indonesia)
- PO-27 CD 142 expression on the leukemic cells from children.**  
N. Lipay\*, T. Shman (Belarus Republic)
- PO-28 Increased thrombin generation (TG) potential of platelets from myeloproliferative neoplasms**  
M. Panova-Noeva\*, M. Marchetti, H.M. Spronk, G. Finazzi, A. Rambaldi, T. Barbui, H. ten Cate, A. Falanga (Italy, The Netherlands)
- PO-29 Calibrated automated thrombogram in cancer patients**  
N. Kolyadko\*, V. Prokhorova, L. Shishlo, T. Tsyryus, S. Lappo, L. Derzhavets (Belarus)
- PO-30 Procoagulant phospholipids in patients with venous thromboembolism and cancer**  
L. Spiezia, C. Radu\*, S. Gavasso, V. Rossetto, C. Abalotti, M. Fadin, P. Dabrilli, B. Woodhams, P. Simioni (Italy, France)
- PO-31 Hypercoagulation in colon and breast cancer patients undergoing surgery as revealed by increased platelet function**  
P. Koliou\*, M. Mitsis, N. Kolaitis, Ch. Batsis, T. Messinis, M. Saranti, G. Vartholomatos, M. Fatouros (Greece)



## Poster Session 3: **HYPERCOAGULATION AND THROMBO/HEMORRHAGIC RISK BIOMARKERS**

### Room E

Chairs: A. D'Angelo (Italy), D. Prisco (Italy)

Sunday - April 25<sup>th</sup>, 2010  
14.00 - 15.15

- PO-32 Prediction of venous thromboembolism in cancer patients by measuring thrombin generation - Results from the Vienna Cancer and Thrombosis Study (CATS)**  
C. Ay\*, R. Simanek, D. Dunkler, J. Thaler, S. Koder, O. Wagner, C. Zielinski, I. Pabinger (Austria)
- PO-33 D-dimer testing to determine duration of anticoagulation and risk of occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study**  
B. Cosmi\*, C. Legnani, A. Tosetto, V. Pengo, A. Ghirarduzzi, A. Alatri, S. Testa, D. Prisco, D. Poli, A. Tripodi, G. Palar-eti, for the PROLONG Investigators\* on behalf of FCSA, Italian Federation of Anticoagulation Clinics (Italy)
- PO-34 Preoperative plasma D-dimer is a predictor of one-year survival in colorectal cancer patients: A prospective clinical cohort study.**  
M. Tornby Stender\*, T.B. Larsen, H.T. Sørensen, O. Thorlacius-Ussing (Denmark)
- PO-35 Loss of angiogenic activity and improvement of hemostatic variables in patients with gastrointestinal stromal tumors (GIST) under Imatinib therapy: a biological evaluation**  
L. Russo\*, M. Mandalà, M. Marchetti, A. Vignoli, S. van Vorkum, R. Labianca, A. Falanga (Italy, The Netherlands)
- PO-36 Detection of circulating tissue factor activity in the plasma of a patient with glioblastoma multiforme: a potential cause of cancer-associated hypercoagulability?**  
J.L. Francis\*, N. Avgeropoulos, E. Coll, H. Desai, L. Robles-Carrillo, M. Amaya, A. Drexler, C. Kulscar, G. Bobustuc, S. Bushnev, A. Amirkhosravi (USA)
- PO-37 Plasma TF levels in colon cancer patients do not alter after total tumor excision**  
P. Koliou\*, M. Mitsis, N. Kolaitis, Ch. Batsis, T. Messinis, M. Saranti, G. Vartholomatos, M. Fatouros (Greece)
- PO-38 Thrombotic risk factors in intensive care unit patients from a cancer hospital: a prospective evaluation**  
E. de Meis\*, M.M. Rosolem, S.G. Silva, L.S.G. Rabello, D.B.S. Azevedo, J.V. Leal, I.C. Marques, M. Soares, J.I.F. Salluh (Brazil)
- PO-39 Selected haemostatic parameters in patients with multiple myeloma and venous thromboembolism**  
J.Staško\*, D.Kotuličová, P.Kubisz (Slovakia)
- PO-40 Abnormal D-dimer level as the first evidence of tumor recurrence: a case report.**  
P.L. Junqueira, P.R. Villaça, A.K.Z. Valim, E. Okazaki, D.A.F. Chamone, E.A. D'Amico\* (Brazil)
- PO-41 Role of PAI-1 in the differential diagnosis of hepatic veno-occlusive disease complicating hematopoietic stem cell transplantation: study in a pediatric population**  
M.T. Sartori\*, S. Cesaro, M. Peruzzo, G. Saggiorato, C. Messina, M. Pillon, E. Calore, L. Spiezia, M. Fadin, A. Pagnan, G. Cella (Italy)
- PO-42 Plasma fibrinogen and survival after cancer diagnosis**  
T. Meade\*, I. dos Santos Silva, B. De Stavola, C. Pizzi (UK)
- PO-43 Hypofibrinolysis in patients with venous thromboembolism and cancer**  
L. Spiezia\*, E. Campello, V. Rossetto, S. Gavasso, F. Dalla Valle, P. Zerbinati, B. Woodhams, P. Simioni (Italy, France)
- PO-44 Retrospective analysis of coagulation parameters at epidural anaesthesia catheter withdrawal after esophageal resection**  
P.A. Anveden, L. Preutz, Å. Rudin, P. Flisberg, E. Eldh, U. Schött\* (Sweden)
- PO-45 The effect of 8- and 24-hour whole-blood storage on coagulation parameters**  
H. Muth\*, D. Peetz, M. Böhm-Weigert, B. Kemkes-Matthes (Germany)
- PO-46 Hyperhomocysteinemia is sensitive marker of thrombotic risk in patients with multiple myeloma**  
V. Shmeleva\*, E. Hait, L. Papayan, K. Abdulkadirov (Russia)
- PO-47 Uncarboxylated matrix Gla-protein (ucMGP) and osteocalcin (ucOC) increase postoperatively after major abdominal cancer and orthopedic surgery.**  
P.A. Anveden, A. Frigyesi, L. Schurgers, U. Schött\* (Sweden, The Netherlands)
- PO-48 The influence of paraprotein on bleeding complications in multiple myeloma**  
I. Djunic\*, I. Elezovic, D. Tomin, J. Bila, D. Antic, A. Vidovic, N. Suvajdzic-Vukovic (Serbia)



## Poster Session 4: MICROPARTICLES

### Room D

Chairs: E. Castoldi (The Netherlands), M. Cattaneo (Italy)

Sunday - April 25<sup>th</sup>, 2010  
15.45 - 17.00

- PO-49 Tumors are the major source of tissue factor-positive microparticles in a mouse model of pancreatic cancer**  
J.-G. Wang\*, J.-J. Yeh, N. Mackman (USA)
- PO-50 The role of breast cancer cells microparticles in thrombogenicity following chemotherapy**  
A. Aharon\*, B. Brenner (Israel)
- PO-51 Elevated numbers and altered subsets of procoagulant microparticles in breast cancer patients using endocrine therapy**  
M.C. Trappenburg\*, M. van Schilfgaarde, E.O. Bredewold, M.C. van Aalderen, H.M. Spronk, H. ten Cate, A. Leyte, W.E. Terpstra (The Netherlands)
- PO-52 Determination of thrombin generation (TG) and procoagulant activity (PCA) expressed by circulating microparticles (MP) in essential thrombocythemia (ET) patients**  
A. Leuzzi\*, M. Marchetti, M. Panova-Noeva, L. Russo, A. Rambaldi, G. Finazzi, B. Woodhams, A. Falanga (Italy, The Netherlands, France)
- PO-53 Platelet derived microparticles induce factor XII mediated thrombin generation**  
H.M. Spronk\*, E. Kilinc, R. van Oerle, K. Hamulyak, T. Renne, H. ten Cate (The Netherlands, Sweden)
- PO-54 Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay and an automated procoagulant assay**  
F. Debaugnies\*, M.A. Azerad, D. Noubouossie, L. Rozen, H.C. Hemker, A. Efira, A. Demulder (Belgium, The Netherlands)
- PO-55 Treatment of the monocytic leukemia cell line THP-1 with anthracyclines increases cellular tissue factor activity and release of tissue factor positive microparticles**  
J. Boles\*, D. Barcel, A.P. Owens III, S. Glover, R. Kasthuri, N. Key, N. Mackman (USA)
- PO-56 Potential contribution of microparticles to the thrombotic risk in high grade glioma**  
M.T. Sartori\*, A. Della Puppa, C.M. Radu, A. Ballin, E. Campello, G. Saggiorato, R. Scienza, D. d'Avell, L. Spiezia, G. Cella, P. Simioni (Italy)
- PO-57 Evaluation of ETP-mipa, a microparticle sensitive thrombin generation assay**  
P.J. Molenaar\*, M. van Schilfgaarde, W.E. Terpstra, A. Leyte (The Netherlands)
- PO-58 Endothelial circulating microparticles in thromboembolism and cancer**  
C. Radu\*, E. Campello, L. Spiezia, C. Bulato, M. Bon, V. Ferri, M. Facchin, P. Simioni (Italy)
- PO-59 Endothelial microparticles levels as markers of tumor response to treatment with anti-angiogenesis agents**  
O. Tillo\*, Y. Xiao, L. Cawkwell, A. Maraveyas (UK)
- PO-60 Changes in procoagulant potential of microparticles in patients with acute myeloid leukemia during chemotherapeutic treatment: behavior of blast-derived microparticles in a phospholipid- and tissue factor-depleted endogenous thrombin potential assay**  
M.C. van Aalderen\*, M.C. Trappenburg, M. van Schilfgaarde, P. J. Molenaar, W. E. Terpstra, A. Leyte (The Netherlands)
- PO-61 Measurement of procoagulant activity of microparticles by the fibrin generation test as a predictor for venous thrombosis in cancer patients**  
A. Kleinjan\*, F.F. van Doormaal, R.J. Berckmans, M. Di Nisio, A. Sturk, P.W. Kamphuisen, R. Nieuwland, H.R. Büller (The Netherlands, Italy)



## POSTER DISCUSSION SESSIONS

### Poster Session 5: PROPHYLAXIS AND TREATMENT

#### Room C

Chairs: G. Johnson (USA), S. Siragusa (Italy)

Sunday - April 25<sup>th</sup>, 2010  
15.45 - 17.00

- PO-62 The implementation of a simple step-wise intervention which dramatically improved the thromboprophylaxis rate in medical cancer patients**  
A. Saha\*, T. Nguyen, C. Watson, S. Mills, M. Madhani, P. MacCallum, S. Slater (UK)
- PO-63 Filling the evidence gap in palliative care: a qualitative study to identify the research agenda for thromboprophylaxis in advanced cancer**  
S.I.R. Noble\*, A. Nelson A, I.G. Finlay (UK)
- PO-64 Cancer, VTE, prognosis and prophylaxis**  
O. Petrova\*, V. Sukhanov (Russian Federation)
- PO-65 Incidence and causes of heparin-induced skin lesions - results of a prospective investigation.**  
M. Schindewolf\*, S. Schwaner, M. Wolter, H. Kroll, R. Kaufmann, W.H. Boehncke, E. Lindhoff-Last, R.J. Ludwig (Germany)
- PO-66 The use of extended peri-operative low molecular weight heparin to improve disease-free survival following surgical resection of colon cancer: a pilot randomized controlled trial**  
M. Carrier\*, R. Boushey, T. Asmis, PS Wells, D. Jonker, R. Auer (Canada)
- PO-67 Long-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism - a randomized controlled trial**  
A. Kleinjan\*, M. Di Nisio, P.W. Kamphuisen, H.R. Buller on behalf of the steering committee (The Netherlands, Italy)
- PO-68 Evolution of long term use of tinzaparin (6 months) in patients with DVT: a prospective study of our clinic**  
E. Dimakakos\*, G. Oikonomopoulos, O. Triadafillou, K. Syrigos (Greece)
- PO-69 Evolution of long term use of tinzaparin (12 months) in patients with pulmonary embolism: a prospective study of our clinic**  
E. Dimakakos\*, O. Triadafillou, G. Oikonomopoulos, K. Syrigos (Greece)
- PO-70 Thromboelastography is an important tool in the anticoagulant management of patient with tumoral thrombosis: a case report.**  
P.L. Junqueira, C.S.S.S. Silva, T.R.F. Rocha, E. Okasaki, A.K.Z. Valim, P.R. Villaça, D.A.F. Chamone, E.A. D'Amico\* (Brazil)
- PO-71 Low molecular weight heparin (LMWH) administration in cancer patients (PTS) with hypercoagulability related complications and carrying brain metastases : a case series**  
F.V. Vitale\*, S. Rotondo, E. Sessa, G. Antonelli, A. Parisi, V. Giaimo, F. Ferraù (Italy)
- PO-72 The likelihood of acute pulmonary embolism in emergency department (ED) patients is not lower among patients taking warfarin.**  
K. Nordenholz\*, D.M. Courtney, C. Kabrhel, P. Richman, C. Moore, H. Smithline, J. Kline (USA)
- PO-73 Venous thromboembolism (VTE) prophylaxis in colorectal cancer surgery patients: the observational SCALA study**  
W. Ageno\*, C.M. Samama, F.A. Anderson on behalf of the SCALA Investigators (Italy, France, USA)
- PO-74 Allergic skin lesions are a rare adverse event under anticoagulatory therapy with fondaparinux - results of a prospective investigation.**  
M. Schindewolf\*, J. Scheuermann, H. Kroll, J. Garbaraviciene, C. Hecking, I. Marzi, M. Wolter, R. Kaufmann, W.H. Boehncke, E. Lindhoff-Last, R.J. Ludwig (Germany)
- PO-75 Efficacy and safety of fondaparinux in the management of strongly suspected heparin-induced thrombocytopenia (HIT): the key role of an early diagnosis**  
S.L. Barco, M. Barone, C. Beltrametti, M. De Amici, V. Giunta, D. Iosub, F. Piovella\* (Italy)
- PO-76 Effectiveness of recombinant factor VIIa in haemorrhagic cancer-related disseminated intravascular coagulation: a case report**  
M. Giorgi Pierfranceschi\*, D. Imberti, S. Orlando, D. Vallisa, E. Michieletti (Italy)
- PO-77 Prophylaxis of DIC and thrombophilia during chemotherapy in gynecologic cancer patients**  
A. Makatsaria, A. Vorobiev\*, Y. Chepurnaya (Russia)
- PO-78 Selection and purification of blood clotting factor VII suitable for therapeutic and treatment purposes**  
S. Madych\*, T. Danysh (Ukraine)





## Poster Session 6: TARGETING THE HEMOSTATIC SYSTEM

### Room E

Chairs: M. Camera (Italy), M.L. Randi (Italy)

Sunday - April 25<sup>th</sup>, 2010  
15.45 - 17.00

- PO-79 Stable overexpression and knockdown of TFPI in breast cancer cells suggest antitumor properties of TFPI**  
B. Stavik\*, G. Skretting, M. Sletten, P. Sandset, N. Iversen (Norway)
- PO-80 The effect of LMWHs on the formation of metastases: a pilot study**  
G. Blaskó\*, Zs. Nagy, V.B. Turcsik (Hungary)
- PO-81 Oversulfated dermatan sulfate (DS) from ascidians, but not mammalian DS, inhibit P-selectin in vitro and metastasis in vivo**  
E.O. Kozłowski\*, M.S.G. Pavão, L. Borsig (Switzerland, Brazil)
- PO-82 Dabigatran etexilate blocks breast cancer progression in vitro and in a 4T1 breast cancer tumor model in mice**  
K. DeFeo, C. Hayes, J. Van Ryn, S.K. Gilmour\*(USA, Germany)
- PO-83 Nadroparin inhibits A549 human lung adenocarcinoma cell proliferation through down-regulation of cyclin B1 and G2/M phase cell-cycle arrest**  
Y. Carmazzi\*, M. Iorio, F. Raggi, S. Cianchetti, T. Neri, C. Cordazzo, R. Vanacore, F. Bogazzi, P. Paggiaro, A. Celi (Italy)
- PO-84 Expression of Tissue Factor (TF) and growth factor receptors on pancreatic cell lines: correlation with TF activity and cell invasion**  
H. Echrich\*, L.A. Madden, J. Greenman, A. Maraveyas (UK)
- PO-85 Effects of an anthocyanin (delphinidin-3-glucoside) from wild blueberries on the proangiogenic and prothrombotic properties of endothelial cells**  
G. Bonacina\*, M. Marchetti, A. Vignoli, E. Diani, M. Porrini, A. Falanga (Italy)
- PO-86 Platelet proteins modified by oxidative stress in myelodysplastic syndromes**  
K. Pimkova\*, R. Kotlin, J. Cermak, J. Suttner, J. E. Dyr (Czech republic)
- PO-87 Prognostic value of vascular endothelial growth factor (VEGF) serum level and immunohistochemical expression in non-treated patient with chronic lymphocytic leukemia**  
D. Antic\*, M.D. Fekete, V. Cokic, M.P. Jovanovic, T. Dragovic, B. Mihaljevic (Serbia)
- PO-88 Prognostic significance of angiogenesis in breast carcinoma**  
E. Kanchev\*, P. Koleva, S. Vicheva, M. Vasileva, K. Kudeva (Bulgaria)
- PO-89 Analysis of the thrombin generation activity expressed by acute promyelocytic leukemia (APL) cells with and without treatment with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA)**  
E. Diani\*, M. Marchetti, L. Russo, D. Balducci, A. Falanga (Italy)
- PO-90 Effect of Betaine on tissue factor expression in human and tumor-associated host cells**  
E. Napoleone, A. Cutrone, D. Cugino, I. Santimone, L. Iacoviello, G. de Gaetano, M.B. Donati, R. Lorenzet\* (Italy)
- PO-91 Leptin upregulates human breast cancer cell line MCF7 expression of tissue factor: a possible role of tumor necrosis factor**  
E. Napoleone, A. Cutrone, M.C. Latella, D. Cugino, L. Iacoviello, G. de Gaetano, M.B. Donati, R. Lorenzet\* (Italy)
- PO-92 Disabled-2 modulates platelet activation and heterotypic interactions with leukocytes**  
C.V. Finkielstein, K.E. Drahos, J.D. Welsh, D.G.S. Capelluto\* (USA)
- PO-93 Very low molecular weight heparins (LMWH) retain the capacity to inhibit endothelial cell migration and capillary-like tube formation induced by tumor cells**  
A. Vignoli\*, M. Marchetti, E. Cantalino, E. Diani, G. Bonacina, A. Falanga (Italy)



# AUTHOR INDEX

## A

Abalotti, C. .... **PO-30**  
 Abbadessa, V. .... **PO-15**  
 Abdulkadirov, K. .... **PO-46**  
 Ageno, W. .... **OC-01, OC-11, PO-07, PO-73**  
 Agnelli, G. .... **DB-02, OC-01, PO-07**  
 Aguirre, M. .... **PO-14**  
 Aharon, A. .... **PO-50**  
 Aissaoui, H. .... **OC-13**  
 Alatri, A. .... **PO-33**  
 Amaya, M. .... **PO-36**  
 Amirkhosravi, A. .... **OC-09, PO-36**  
 Anderson, F.A. .... **PO-73**  
 Angchaisuksiri, P. .... **PO-10**  
 Antic, D. .... **PO-48, PO-87**  
 Antonelli, G. .... **PO-71**  
 Anveden, P.A. .... **PO-44, PO-47**  
 Arnason, J.E. .... **OC-15**  
 Artoni, A. .... **OC-06**  
 Asmis, T. .... **PO-66**  
 Atkins, H. .... **PO-17**  
 Auer, R. .... **PO-17, PO-66**  
 Avery, G. .... **PO-09**  
 Avgeropoulos, N. .... **PO-36**  
 Ay, C. .... **PO-32**  
 Azerad, M.A. .... **PO-54**  
 Azevedo, D.B.S. .... **PO-38**

## B

Babakova, S. .... **PO-25**  
 Bakker-Abreu, I. .... **PO-19**  
 Balducci, D. .... **PO-89**  
 Ballin, A. .... **PO-56**  
 Banerjee, S. .... **OC-15**  
 Barbui, T. .... **PO-28**  
 Barcel, D. .... **PO-55**  
 Barco, S.L. .... **PO-75**  
 Barone, M. .... **PO-75**  
 Batsis, Ch. .... **PO-31, PO-37**  
 Becattini, C. .... **PO-07**  
 Bell, J. .... **PO-17**  
 Belting, M. .... **OC-12**  
 Beltrametti, C. .... **PO-75**  
 Berckmans, R.J. .... **PO-61**  
 Berdel, W.E. .... **SS-16**  
 Beyer-Westendorf, J. .... **SS-19**  
 Bichenkov, O. .... **PO-25**  
 Bila, J. .... **PO-48**  
 Blaskó, G. .... **PO-80**

Bobustuc, G. .... **PO-36**  
 Boehncke, W.H. .... **PO-65, PO-74**  
 Bogazzi, F. .... **PO-83**  
 Böhm-Weigert, M. .... **PO-45**  
 Boles, J. .... **PO-55**  
 Bon, M. .... **PO-58**  
 Bonacina, G. .... **PO-85, PO-93**  
 Bordet, H.J.C. .... **OC-13**  
 Borsig, L. .... **PL-08, PO-81**  
 Boukerche, H. .... **OC-13**  
 Boushey, R. .... **PO-17, PO-66**  
 Bozas, G. .... **OC-02, PO-09**  
 Bredewold, E.O. .... **PO-51**  
 Bremer, C.  
 Brenner, B. .... **PO-50**  
 Bucciarelli, P. .... **OC-06**  
 Bucherini, E. .... **OC-11**  
 Bulato, C. .... **PO-58**  
 Büller, H.R. .... **PL-11, PO-03, PO-06, PO-12, PO-61, PO-67**  
 Bullian, P. .... **PO-16**  
 Bundred, N.J. .... **PO-23**  
 Burgos, R. .... **PO-14**  
 Bushnev, S. .... **PO-36**  
 Byrne, G.J. .... **PO-23**

## C

Calore, E. .... **PO-41**  
 Campayo, M. .... **PO-01, PO-08**  
 Campello, E. .... **PO-43, PO-56, PO-58**  
 Canciani, M.T. .... **OC-06**  
 Cantalino, E. .... **PO-21, PO-93**  
 Capelluto, D.G.S. .... **PO-92**  
 Carey, B. .... **PO-05**  
 Carmazzi, Y. .... **PO-83**  
 Carneiro, J.D.A. .... **OC-14**  
 Carneiro-Lobo, T.C. .... **PO-19**  
 Carrier, M. .... **PO-17, PO-66**  
 Cawkwell, L. .... **PO-59**  
 Ceconello, M. .... **PO-16**  
 Celi, A. .... **PO-83**  
 Cella, G. .... **PO-41, PO-56**  
 Cermak, J. .... **PO-24, PO-86**  
 Cesaro, S. .... **PO-41**  
 Chacon, R. .... **PO-14**  
 Chamone, D.A.F. .... **OC-14, PO-40, PO-70**  
 Chepurnaya, Y. .... **PO-77**  
 Cianchetti, S. .... **PO-83**  
 Cohen, A.T. .... **PL-04**

Cokic, V. .... **PO-87**  
 Coll, E. .... **PO-36**  
 Conti, R. .... **PO-14**  
 Cordazzo, C. .... **PO-83**  
 Cormaci, O. .... **OC-11**  
 Cosmi, B. .... **PO-33**  
 Courtney, D.M. .... **PO-72**  
 Cozzi, G. .... **OC-06**  
 Cravero, P. .... **PO-14**  
 Cuccurullo, F. .... **PO-06**  
 Cugino, D. .... **PO-90, PO-91**  
 Cutrone, A. .... **PO-90, PO-91**

## D

Da Silva de Oliveira, A. .... **OC-05**  
 Dabrilili, P. .... **PO-30**  
 Dabrowski, T. .... **PO-04, PO-11**  
 D'Alessio, A. .... **OC-11**  
 Dalla Valle, F. .... **PO-43**  
 D'Amico, E.A. .... **OC-14, PO-40, PO-70**  
 Danysh, T. .... **PO-78**  
 Dargaud, Y. .... **OC-13**  
 d'Avell, D. .... **PO-56**  
 Davila, M. .... **OC-09**  
 De Amici, M. .... **PO-75**  
 de Gaetano, G. .... **PO-90, PO-91**  
 de Meis, E. .... **PO-38**  
 De Stavola, B. .... **PO-42**  
 De Tursi, M. .... **PO-06**  
 Debaugnies, F. .... **PO-54**  
 DeFeo, K. .... **PO-82**  
 Deitchman, D. .... **OC-03**  
 Della Puppa, A. .... **PO-56**  
 Demulder, A. .... **PO-54**  
 Dentali, F. .... **OC-01, PO-07**  
 Derzhavets, L. .... **PO-29**  
 Desai, H. .... **PO-36**  
 Dhillon, G.S. .... **OC-15**  
 Di Micco, P. .... **OC-11**  
 Di Nisio, M. .... **PO-06, PO-12, PO-61, PO-67**  
 Diani, E. .... **PO-21, PO-85, PO-89, PO-93**  
 Dignat-George, F. .... **OC-10**  
 Dimakakos, E. .... **PO-68, PO-69**  
 Djunic, I. .... **PO-48**  
 Dolznig, H. .... **OC-04**  
 Donati, M.B. .... **SS-10, PO-90, PO-91**  
 Donnelly, O.G. .... **PO-05**



# AUTHOR INDEX

dos Santos Silva, I. .... **PO-42**  
 Dragovic, T. .... **PO-87**  
 Drahos, K.E. .... **PO-92**  
 Drexler, A. .... **PO-36**  
 Dubois, C. .... **OC-10**  
 Dunkler, D. .... **PO-32**  
 Dutra-Oliveira, A. .... **PO-19**  
 Dyr, J.E. .... **PO-24, PO-86**

## E

Echrish, H. .... **PO-84**  
 Efira, A. .... **PO-54**  
 Eldh, E. .... **PO-44**  
 Elezovic, I. .... **PO-48**  
 Elice, F. .... **SS-05**  
 Esclanate, C.P. .... **OC-03**  
 Evangelou, A. .... **PO-20**

## F

Facchin, M. .... **PO-58**  
 Fadin, M. .... **PO-30, PO-41**  
 Fai, B. .... **PO-16**  
 Falanga, A. ... **PO-21, PO-28, PO-35, PO-52, PO-85, PO-89, PO-93**  
 Farge, D. .... **PL-12**  
 Farrús, B. .... **PO-01, PO-08**  
 Fatouros, M. .... **PO-31, PO-37**  
 Federici, A.B. .... **OC-06**  
 Fekete, M.D. .... **PO-87**  
 Ferrante, N. .... **PO-06**  
 Ferraù, F. .... **PO-71**  
 Ferri, V. .... **PO-58**  
 Finazzi, G. .... **PO-28, PO-52**  
 Finkelstein, C.V. .... **PO-92**  
 Finlay, I.G. .... **PO-63**  
 Fisher, P.B. .... **OC-13**  
 Flisberg, P. .... **PO-44**  
 Foncuberta, M.C. .... **PO-14**  
 Font, A. .... **OC-08**  
 Font, C. .... **PO-01, PO-08**  
 Francis, J.L. .... **OC-09, PO-36**  
 Francischetti, I.M.B. .... **OC-05**  
 Freyssinet, J-M. .... **SS-08**  
 Frigyesi, A. .... **PO-47**  
 Fulfaro, F. .... **PO-15**  
 Fyfe, D. .... **OC-02**

## G

Galli, L. .... **PO-07**  
 Galluci, P. .... **OC-11**

Garbaraviciene, J. .... **PO-74**  
 García-Mouriz, A. .... **PO-02**  
 Gardiner, E. .... **OC-02**  
 Garin-Chesa, P. .... **OC-04**  
 Gascon, P. .... **PO-01, PO-08**  
 Gavasso, S. .... **PO-30, PO-43**  
 Gebbia, N. .... **PO-15**  
 Ghirarduzzi, A. .... **PO-33**  
 Giaimo, V. .... **PO-71**  
 Gianni, M. .... **PO-07**  
 Gilmour, S.K. .... **PO-82**  
 Giorgi Pierfranceschi, M. .... **OC-01, PO-76**  
 Giornelli, G. .... **PO-14**  
 Giunta, V. .... **PO-75**  
 Glover, S. .... **PO-55**  
 Godina, M. .... **PO-13**  
 González Billalabeitia, E. .... **OC-08**  
 Gorynski, E. .... **OC-15**  
 Grabau, D. .... **OC-12**  
 Greenman, J. .... **PO-84**

## H

Hahn, N. .... **PO-18**  
 Hait, E. .... **PO-46**  
 Hamulyak, K. .... **PO-53**  
 Harahap, A.R. .... **PO-26**  
 Haslinger, C. .... **OC-04**  
 Hayes, C. .... **PO-82**  
 Hecking, C. .... **PO-74**  
 Heiden, M. .... **PO-18**  
 Hemker, H.C. .... **PO-54**  
 Hong, S. .... **OC-15**

## I

Iacobelli, S. .... **PO-06**  
 Iacoviello, L. .... **PO-90, PO-91**  
 Imberti, D. ... **OC-01, PO-07, PO-76**  
 Iorio, M. .... **PO-83**  
 Iosub, D. .... **PO-75**  
 Iversen, N. .... **PO-22, PO-79**

## J

Jones, J. .... **PO-05**  
 Jonker, D. .... **PO-66**  
 Jönsson, P-E. .... **OC-12**  
 Jovanovic, M.P. .... **PO-87**  
 Julian, J.A. .... **OC-03**  
 Junqueira, P.L. .... **PO-40, PO-70**

## K

Kabrhel, C. .... **PO-72**  
 Kakkar, A.K. .... **PL-05**  
 Kamphuisen, P.W. .... **PO-12, PO-61, PO-67**  
 Kanchev, E. .... **PO-88**  
 Karkabounas, S. .... **PO-20**  
 Kasthuri, R. .... **PO-55**  
 Kaufmann, R. .... **PO-65, PO-74**  
 Kemkes-Matthes, B. .... **PO-45**  
 Key, N. .... **SS-07, PO-55**  
 Khorana, A.A. .... **PL-01**  
 Kilinc, E. .... **PO-53**  
 Kirwan, C.C. .... **PO-23**  
 Kleinjan, A. ... **PO-12, PO-61, PO-67**  
 Kline, J. .... **PO-72**  
 Koder, S. .... **PO-32**  
 Kok, M. .... **PO-03**  
 Kolaitis, N. .... **PO-31, PO-37**  
 Koleva, P. .... **PO-88**  
 Koliou, P. .... **PO-31, PO-37**  
 Kolyadko, N. .... **PO-29**  
 Kotlin, R. .... **PO-24, PO-86**  
 Kotuličová, D. .... **PO-39**  
 Kozlowski, E.O. .... **PO-81**  
 Kroll, H. .... **PO-65, PO-74**  
 Kubisz, P. .... **PO-39**  
 Kuderer, N.M. .... **SS-18**  
 Kudeva, K. .... **PO-88**  
 Kulscar, C. .... **PO-36**  
 Kuno Møller, B. .... **PO-04**

## L

La Marca, G. .... **OC-11**  
 Labianca, R. .... **PL-13, PO-35**  
 Lacroix, R. .... **OC-10**  
 Lappo, S. .... **PO-29**  
 Larsen, A.C. .... **PO-04, PO-11**  
 Larsen, T.B. .... **PO-34**  
 Latella, M.C. .... **PO-91**  
 Leal, J.V. .... **PO-38**  
 Lecumberri, R. .... **OC-08, PO-02**  
 Lee, A.Y.Y. .... **PL-02**  
 Legnani, C. .... **PO-33**  
 Leuzzi, A. .... **PO-52**  
 Levandovsky, M. .... **OC-15**  
 Levine, M.N. .... **DB-01, OC-03**  
 Leyte, A. .... **PO-51, PO-57, PO-60**  
 Liasko, R. .... **PO-20**



# AUTHOR INDEX

Liebman, H.A. .... **OC-03**  
 Lima, L.G. .... **OC-05**  
 Lindhoff-Last, E. .... **PO-65, PO-74**  
 Lipay, N. .... **PO-27**  
 Lo Coco, L. .... **OC-11, PO-15**  
 Lofts, F. .... **OC-02**  
 Lombardo, D. .... **OC-10**  
 López Vivanco, G. .... **OC-08**  
 Lorenzet, R. .... **PO-90, PO-91**  
 Ludwig, R.J. .... **PO-65, PO-74**  
 Lyman, G.H. .... **PL-14**

## M

MacCallum, P. .... **PO-62**  
 Machado, D.E. .... **OC-05**  
 MacKenzie, L. .... **PO-17**  
 Mackman, N. .... **PO-49, PO-55**  
 Madden, L.A. .... **PO-84**  
 Madhani, M. .... **PO-62**  
 Madych, S. .... **PO-78**  
 Majek, P. .... **PO-24**  
 Makatsaria, A. .... **PO-77**  
 Makris, M.P. .... **PO-20**  
 Makris, P.E. .... **PO-20**  
 Malato, A. .... **OC-01, OC-11, PO-15**  
 Mandalà, M. .... **PO-35**  
 Maraveyas, A. .... **OC-02, PO-09, PO-59, PO-84**  
 Marchetti, M. **PO-21, PO-28, PO-35, PO-52, PO-85, PO-89, PO-93**  
 Mariano-Oliveira, A. .... **PO-19**  
 Marques, I.C. .... **PO-38**  
 Martin, C. .... **PO-14**  
 Marzi, I. .... **PO-74**  
 Mascheroni, D. .... **OC-11**  
 Masia, G. .... **PO-16**  
 Massuti, B. .... **OC-08**  
 Matveeva, A. .... **PO-25**  
 McAllister, R.E. .... **OC-07**  
 McCollum, C.N. .... **PO-23**  
 McDowell, G. .... **PO-23**  
 Meade, T. .... **PO-42**  
 Menegon, P. .... **PO-13**  
 Messina, C. .... **PO-41**  
 Messinis, T. .... **PO-31, PO-37**  
 Metsios, A. .... **PO-20**  
 Michieletti, E. .... **PO-76**  
 Mihaljevic, B. .... **PO-87**  
 Mills, S. .... **PO-62**

Mitsis, M. .... **PO-31, PO-37**  
 Molenaar, P.J. .... **PO-57, PO-60**  
 Monreal, M. .... **SS-06**  
 Monteiro, R.Q. .... **OC-05, PO-19**  
 Moore, C. .... **PO-72**  
 Muth, H. .... **PO-45**

## N

Nadir, Y. .... **PL-09**  
 Nagy, Zs. .... **PO-80**  
 Nanus, D.M. .... **OC-15**  
 Napoleone, E. .... **PO-90, PO-91**  
 Nasciutti, L.E. .... **OC-05**  
 Négrier, C. .... **OC-13**  
 Nelson A, A. .... **PO-63**  
 Neri, T. .... **PO-83**  
 Nguyen, T. .... **PO-62**  
 Nieuwland, R. .... **PO-61**  
 Nitti, C. .... **OC-01**  
 Noble, S.I.R. .... **PO-63**  
 Nordenholz, K. .... **PO-72**  
 Noubouossie, D. .... **PO-54**

## O

O' Connor, J. .... **PO-14**  
 O'Brien, M.C. .... **OC-03**  
 Ochoa, P. .... **PO-14**  
 Odone-Filho, V. .... **OC-14**  
 Oikonomopoulos, G. .... **PO-68, PO-69**  
 Okasaki, E. .... **PO-40, PO-70**  
 Orlando, S. .... **PO-76**  
 Ortega, V. .... **PO-08**  
 Otten, H.-M.M.B. .... **PO-03**  
 Owens III, A.P. .... **PO-55**

## P

Pabinger, I. .... **PL-03, PO-32**  
 Paggiaro, P. .... **PO-83**  
 Pagnan, A. .... **PO-41**  
 Palareti, G. .... **PL-07, PO-33**  
 Palumbo, J.S. .... **SS-02**  
 Panicot-Dubois, L. .... **OC-10**  
 Panizo, E. .... **PO-02**  
 Panova-Noeva, M. .... **PO-28, PO-52**  
 Papayan, L. .... **PO-46**  
 Páramo, J.A. .... **PO-02**  
 Parisi, A. .... **PO-71**  
 Pavão, M.S.G. .... **PO-81**  
 Peetz, D. .... **PO-45**  
 Pengo, M.F. .... **SS-12**

Pengo, V. .... **PO-33**  
 Peruzzo, M. .... **PO-41**  
 Petersen, L.C. .... **OC-05**  
 Petracci, F. .... **PO-14**  
 Petrillo, K. .... **OC-15**  
 Petrova, O. .... **PO-64**  
 Pillon, M. .... **PO-41**  
 Pimkova, K. .... **PO-24, PO-86**  
 Piovela, F. .... **PO-75**  
 Pizzi, C. .... **PO-42**  
 Plantier, J.L. .... **OC-13**  
 Poli, D. .... **PO-33**  
 Porreca, E. .... **PO-06**  
 Porrini, M. .... **PO-85**  
 Prantera, T. .... **OC-11**  
 Preutz, L. .... **PO-44**  
 Prévost, C. .... **OC-13**  
 Prisco, D. .... **PO-33**  
 Prokhorova, V. .... **PO-29**  
 Proppe, D. .... **OC-02**  
 Putti, M.C. .... **SS-17**

## R

Rabello, L.S.G. .... **PO-38**  
 Radhakrishna, G. .... **PO-05**  
 Radu, C. .... **PO-30, PO-56, PO-58**  
 Raggi, F. .... **PO-83**  
 Rak, J.W. .... **SS-03**  
 Ramasamy, S. .... **PO-09**  
 Rambaldi, A. .... **PO-28, PO-52**  
 Ramirez, L.M. .... **OC-03**  
 Recchia, F. .... **OC-11**  
 Reguart, N. .... **PO-01**  
 Renne, T. .... **PO-53**  
 Reverter, J.C. .... **PO-01, PO-08**  
 Rezzonico, F. .... **OC-06**  
 Richman, P. .... **PO-72**  
 Risom Kristensen, S. .... **PO-04**  
 Riva, N. .... **PO-07**  
 Robles-Carrillo, L. .... **OC-09, PO-36**  
 Rocha, E. .... **OC-08**  
 Rocha, T.R.F. .... **PO-70**  
 Romagnoli, E. .... **PO-16**  
 Rosolem, M.M. .... **PO-38**  
 Rossetto, V. .... **PO-30, PO-43**  
 Rotondo, S. .... **OC-11, PO-71**  
 Roy, R. .... **OC-02**  
 Rozen, L. .... **PO-54**  
 Rudin, A. .... **PO-44**  
 Ruf, W. .... **SS-01, OC-12**



# AUTHOR INDEX

Rupp, C. .... **OC-04**  
 Russo, L. .... **PO-35, PO-52, PO-89**  
 Rydén, L. .... **OC-12**

## S

Salluh, J.I.F. .... **PO-38**  
 Salvi, A. .... **OC-01**  
 Samama, C.M. .... **PO-73**  
 Sanchez Avalos, J. .... **PO-14**  
 Sandset, P.M. .... **PO-22, PO-79**  
 Santimone, I. .... **PO-90**  
 Santoro, R. .... **OC-11**  
 Sanz, M.A. .... **SS-04**  
 Saranti, M. .... **PO-31, PO-37**  
 Sartori, M.T. .... **PO-41, PO-56**  
 Schaffner, F. .... **OC-12**  
 Scharfstein, J. .... **PO-19**  
 Scheuermann, J. .... **PO-74**  
 Schindewolf, M. .... **PO-65, PO-74**  
 Schött, U. .... **PO-44, PO-47**  
 Schurgers, L. .... **PO-47**  
 Schwaner, S. .... **PO-65**  
 Schweifer, N. .... **OC-04**  
 Scienza, R. .... **PO-56**  
 Segati, R. .... **PO-16**  
 Seitz, R. .... **PO-18**  
 Selzer, J. .... **OC-15**  
 Sessa, E. .... **PO-71**  
 Seth, R. .... **PO-17**  
 Sgouros, J. .... **OC-02**  
 Shishlo, L. .... **PO-29**  
 Shman, T. .... **PO-27**  
 Shmeleva, V. .... **PO-46**  
 Silva, C.S.S.S. .... **PO-70**  
 Silva, S.G. .... **PO-38**  
 Simanek, R. .... **PO-32**  
 Simioni, L. .... **PO-16**  
 Simioni, P. .... **PO-30, PO-43, PO-56, PO-58**  
 Siragusa, S. .... **OC-01, OC-11, PO-15**  
 Skretting, G. .... **PO-22, PO-79**  
 Slater, S. .... **PO-62**  
 Sletten, M. .... **PO-79**  
 Smithline, H. .... **PO-72**  
 Soares, M. .... **PO-38**  
 Solheim, E. .... **PO-22**  
 Sørensen, H.T. .... **PO-34**  
 Spadaro, P. .... **OC-11**  
 Spiezia, L. .... **PO-30, PO-41, PO-43, PO-56, PO-58**  
 Spronk, H.M. .... **PO-28, PO-51, PO-53**

Squizzato, A. .... **OC-01, PO-07**  
 Stasko, J. .... **PO-39**  
 Stavik, B. .... **PO-22, PO-79**  
 Streiff, M.B. .... **PL-15**  
 Sturk, A. .... **PO-61**  
 Sukhanov, V. .... **PO-64**  
 Sukrisman, L. .... **PO-26**  
 Sunesen, K.G. .... **PO-11**  
 Sutrisna, B. .... **PO-26**  
 Suttar, J. .... **PO-24, PO-86**  
 Suvajdzic-Vukovic, N. .... **PO-48**  
 Swinson, D. .... **PO-05**  
 Syrigos, K. .... **PO-68, PO-69**

## T

Tagawa, S.T. .... **OC-15**  
 Tambunan, K.L. .... **PO-26**  
 Tartas, N. .... **PO-14**  
 Tasinato, R. .... **PO-13**  
 Tàssies, D. .... **PO-01, PO-08**  
 ten Cate, H. .... **PO-21, PO-28, PO-51, PO-53**  
 Terpstra, W.E. .... **PO-51, PO-57, PO-60**  
 Testa, S. .... **PO-33**  
 Thaler, J. .... **PO-32**  
 Thomas, G.M. .... **OC-10**  
 Thorlacius-Ussing, O. .... **PO-04, PO-11, PO-34**  
 Thorpe, P.E. .... **SS-14**  
 Tillo, O. .... **PO-59**  
 Tomin, D. .... **PO-48**  
 Tornby Stender, M. .... **PO-34**  
 Tosetto, A. .... **PO-33**  
 Trappenburg, M.C. .... **PO-51, PO-60**  
 Triadafilou, O. .... **PO-68, PO-69**  
 Tripodi, A. .... **PO-33**  
 Tsyru, T. .... **PO-29**  
 Turcsik, V.B. .... **PO-80**

## U

Urbano, O. .... **OC-11**

## V

Valim, A.K.Z. .... **PO-40, PO-70**  
 Vallisa, D. .... **PO-76**  
 van Aalderen, M.C. .... **PO-51, PO-60**  
 van Doormaal, F.F. .... **PO-61**  
 van Houwelingen, J.C. .... **PO-03**  
 Van Noorden, C.J.F. .... **PL-10**  
 van Oerle, R. .... **PO-53**  
 van Ryn, J. .... **OC-04, PO-82**

van Schilfgaarde, M. .... **PO-51, PO-57, PO-60**  
 van Sluis, G.L. .... **SS-15, PO-03**  
 van Vorkum, S. .... **PO-35**  
 Vanacore, R. .... **PO-83**  
 Varea, S. .... **PO-02**  
 Vartholomatos, G. .... **PO-31, PO-37**  
 Vasilenko, I. .... **PO-25**  
 Vasileva, M. .... **PO-88**  
 Vecchiato, A. .... **PO-13**  
 Veltsistas, P. .... **PO-20**  
 Venco, A. .... **OC-01, PO-07**  
 Verberne, L. .... **PO-03**  
 Vicheva, S. .... **PO-88**  
 Vidal, L. .... **PO-08**  
 Vidovic, A. .... **PO-48**  
 Vignoli, A. .... **PO-35, PO-85, PO-93**  
 Villac, a, P.R. .... **PO-40, PO-70**  
 Vincents Fisker, R. .... **PO-04, PO-11**  
 Viñolas, N. .... **PO-01**  
 Vitale, F.V. .... **PO-71**  
 Vitale, J. .... **OC-01**  
 Vorobiev, A. .... **PO-77**

## W

Wagner, O. .... **PO-32**  
 Wang, J.-G. .... **PO-49**  
 Waters, J. .... **OC-02**  
 Watson, C. .... **PO-62**  
 Wedgewood, K.R. .... **OC-02**  
 Weitz, I. .... **SS-13**  
 Weitz, J.I. .... **PL-06**  
 Wells, P.S. .... **PO-66**  
 Welsh, J.D. .... **PO-92**  
 Wolter, M. .... **PO-65, PO-74**  
 Woodhams, B. .... **PO-30, PO-43, PO-52**  
 Worasayan, D. .... **PO-10**  
 Wun, T. .... **SS-11**

## X

Xiao, Y. .... **PO-59**

## Y

Yeh, J.-J. .... **PO-49**  
 Yilmaz, M.K. .... **PO-11**

## Z

Zerbinati, P. .... **PO-43**  
 Zielinski, C. .... **PO-32**  
 Zwicker, J.I. .... **SS-09**  
 Zylberman, M. .... **PO-14**





## GENERAL INFORMATION

### Meeting venue

The Conference takes place in Stresa at the Palazzo dei Congressi, Piazzale Europa, 3.

### Organizing Secretariat

#### Servizi C.E.C. Srl

Servizi Congressuali ed Eventi Culturali  
Via Verdi 18 - 24121 Bergamo - Italy  
Phone +39.035.249899 - Fax +39.035.237852  
On site phone +39.331.6491430  
e-mail: info@icthic.com

### Registration desk

The registration desk is located in the entrance hall of the Congress Palace.

It is staffed continuously every day of the conference. The staff is at your disposal for any information. Facilities available at the registration desk include:

#### *On-site registration*

Fees for on-site registration are:

- Full (Regular): Euro 490
- Student: Euro 100
- Accompanying person: Euro 120

#### *Message boards*

Any late change in the program of the conference or personal messages will be notified here.

#### *Telephone and fax*

Available on request.

#### *Computing, printing and xeroxing*

Available on request.

### Internet Point

It is located at the ground floor, close to the registration desk.

### Continuing Medical Education

The 5<sup>th</sup> International Conference on Thrombosis and Hemostasis Issues in Cancer has been granted for CME accreditation by:

- **European Hematology Association (EHA)**

#### **15.5 CME points**

for European Hematologists.

The program of the 5<sup>th</sup> ICTHIC has been reviewed and approved for CME accreditation by the European Hematology Association CME Unit.

The EHA-CME Unit has approved this educational activity for a maximum number of 15.5 CME credits. Each physician should only claim credits for time that she/he actually spent in the educational activity.

- **European Society for Medical Oncology (ESMO)**

#### **14 Category I ESMO-MORA points**

for European Medical Oncologists

- **Italian Ministry of Health**

(for Italian Participants only)

#### **10 CME (ECM) Credits**

for Medical Doctors and Biologists

- **European Union of Medical Specialists (UEMS)**

#### **12 European CME credits (ECMEC)**

by the European Accreditation Council for Continuing Medical Education (EACCME).

UEMS credits are recognized by the American Medical Association (AMA).

Physicians (MDs, DOs or equivalent international degree) may have their UEMS-EACCME credit converted to AMA PRA Category 1 Credit™ by applying to the AMA.

The instructions and the forms for claiming CME Credits are in the Congress bag.





## GENERAL INFORMATION

### Delegate Badge

All delegates are kindly requested to wear the badge throughout the conference. Only badge holders will be admitted to the Conference, Exhibition, Welcome Cocktail, Coffee/Tea breaks and Lunches. For the Social Events please bring with you the tickets delivered to you at registration.

Name badges are colored as follows:

<b>Delegate</b>	<b>Green</b>
<b>Faculty</b>	<b>Blue</b>
<b>Accompanying person</b>	<b>Grey</b>
<b>Sponsor</b>	<b>Red</b>

### Certificates of Attendance

They will be delivered at the registration desk starting from 13.00 on Sunday April 25<sup>th</sup>.

### Posters

#### Mounting:

From 9.00 Friday April 23<sup>rd</sup>, in rooms D, E, and on the mezzanine floor\*.

\*On Sunday April 25<sup>th</sup> at 12.00, all posters mounted on the mezzanine floor will be moved by the organizing staff into room C for the discussion sessions.

#### Poster view:

From 14.00 Friday April 23<sup>rd</sup> to 11.00 Sunday April 25<sup>th</sup>.

#### Attendance:

During the discussion (see below)

#### Discussion:

There will be 6 Poster Discussion Sessions (1h 15 min each), held on Sunday April 25<sup>th</sup> from 14.00 to 15.15 and from 15.45 to 17.00, each guided by two co-chairs. See the program of the poster discussion sessions for details (pages 16-21). The presenting Authors are required to attend during the discussion.

#### Dismantling:

From 17.00 to 18.00 on Sunday April 25<sup>th</sup>. After this time the posters will be destroyed by the congress organizers.

### Slide Center

Slide center is located at the ground floor in front of the registration desk. All presenters should check in their slides or diskette/CD-ROM containing a PowerPoint presentation no later than 2 hours prior to the start of their session.

### Language

The official language of the Conference is English. Translations are not provided.

### Meals

Coffee/tea breaks and lunches are included in the Conference fee and are served in the catering areas located at the ground floor and second floor.

### Cloakroom


Coats and bags may be left in the designated area under the ground floor.

### Exhibition

The commercial exhibition is located in the foyer at the ground floor. The exhibition opening times are the same of the Conference.




## Ground Floor



## Ground Floor

- 1 Internet point
- 2 Registration Desk
- 3 Slide Center
- 4 Exhibition and coffee break area
- 5 Auditorium
- 6 Cloakroom


## Mezzanine Floor



## Mezzanine Floor

- 1 Coffee break area and mounting/view of Posters of Poster Sessions 1 & 5

## First Floor



## First Floor

- 1 Room C
- 2 Room D
- 3 Room E
- 4 Room Panoramica



### Social Events

(for both registered participants and accompanying persons)

#### Welcome Cocktail

**Friday April 23<sup>rd</sup>, 19.00**

Included in the Registration Fee. This event will take place at the Palazzo dei Congressi (meeting venue) in the Room Panoramica.

#### Gala Dinner

**Saturday April 24<sup>th</sup>, 19.30**

Included in the Registration Fee. This event will take place at the Hotel Regina Palace.

#### Farewell Party

**Sunday April 25<sup>th</sup>, 19.30**

*Meeting point: Palazzo dei Congressi di Stresa at 18.45*

A reservation fee of € 50,00 (boat included) must be paid in advance. This event will take place on the island Isola Bella.

### Excursions

(for registered accompanying persons only, included in the registration fee)

#### Visit of Isola Pescatori and Isola Madre

**Saturday April 24<sup>th</sup>, 08.45 - 13.00**

*Meeting point: Palazzo dei Congressi di Stresa at 08.45*

Half day by boat on Lake Maggiore.

Guests will board the boat from the main jetty and sail across the lake admiring the beautiful scenery. They will arrive on Isola Madre, where they'll be guided throughout the Borromeo palace and the wonderful English style gardens, its peacocks pheasants and parrots, who walk freely around the island.

Guests will then visit the Isola Superiore dei Pescatori, the fisherman's island, where it will be possible to admire the small shops and the small village, before returning to Stresa by boat.



#### Visit of Botanical Gardens of Villa Taranto (Pallanza)


**Sunday April 25<sup>th</sup>, 08.45 - 13.00**

*Meeting point: Palazzo dei Congressi di Stresa at 08.45*

In 1931 the Scottish capt. Neil McEacharn decided to buy the land and transform it in an English Garden Style. Thousands of plants, brought from all over the world, many of them rare and unique in Europe, were planted in his garden, named Villa Taranto. The botanical richness of Villa Taranto's gardens consist of nearly 1,000 non-native plants and around 20,000 different varieties of plants with particular botanical importance.

From the romantic Valletta to the carpets of Heather, from the glass houses with "Victoria Amazonica" to the Azalea, Marple, Rhododendron and Camelia avenues, from the gardens of Dahlias with more than 300 varieties to the myriad hues of spring blooms, with the background of the Italian Garden or in the yellow glow of autumn, Villa Taranto rewards the visitor with endless scenes of changing beauty. The Villa, that gives name to the gardens, is not open to the public, since it is used as seat of the Prefecture of the Province of Verbano-Cusio-Ossola.

Guests will depart from Stresa by private motorboat, sailing through the Borromean Gulf till the botanical gardens of Villa Taranto. After the visit there will be the possibility of a short stop in the typical town of Pallanza, before returning to Stresa by boat.







### Lake Maggiore

Reflecting mirrors of water, surrounded by the beautiful scenery of parks, gardens and mountain routes from where you can admire seven lakes, the Po Valley in the Italian and Swiss Alps. This is how Lake Maggiore and Lake Mergozzo present themselves. Of Lake Maggiore what strikes at first is the sight of the magnificent islands that form, together with historic castles and the Island of Cannero and the Island of St. John the Baptist, a beautiful archipelago. Isola Bella, home to the Borromeo Palace (1670), Isola dei Pescatori, typical maze of picturesque lanes and alleys, and, Isola Madre, with its famous botanical gardens rich in rare plants and animals who live in freedom.



### Stresa

The name of Stresa first appeared in documents dated 998; it has been under the jurisdiction and therefore property of Borromei and Visconti families until the 19<sup>th</sup> century, when, thanks to the presence of famous personages like Rosmini, Manzoni and the Duchess of Genoa, that is Elizabeth of Sassonia, Stresa began to gain prestige.

The construction of the Simplon railway, at the beginning of the 20<sup>th</sup> century, gave Stresa international fame.

From the promenade, sprinkled with grand hotels, villas, parks and gardens, you can have a magnificent view of the three islands, and of the Alps far away.

The nearness of big cities, such as Turin and Milan as well as their airports, the Congress Palace, the hotels which combine up-to-date facilities with a long tradition of hospitality, the breath-taking beauty of gardens and parks, the mild climate, and many other characteristics, all make Stresa an ideal place for the tourists.







# MAP OF STRESA


**Grand Hotel Bristol**




**Hotel La Palma**



**Hotel Stresa Astoria**




**Train Station**  
Stresa



**Hotel Regina Palace**



**Palazzo dei Congressi di Stresa**  
(Meeting Venue)



**Hotel Moderno**



## ORGANIZING SECRETARIAT



**C.E.C. Srl**

**Servizi Congressuali ed Eventi Culturali**

Via G. Verdi 18 - 24121 Bergamo - Italy

Phone +39.035.249899 - Fax +39.035.237852

E-mail: [info@icthic.com](mailto:info@icthic.com)

## SCIENTIFIC SECRETARIAT

**Anna Falanga**

**Marina Marchetti**

**Alfonso Vignoli**

Division of Immunohematology and Transfusion Medicine  
& Hemostasis and Thrombosis Center

A.O. Ospedali Riuniti di Bergamo

Largo Barozzi, 1 - 24128 Bergamo, Italy

e-mail: [icthic2010@yahoo.com](mailto:icthic2010@yahoo.com)

**[www.icthic.com](http://www.icthic.com)**